Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
AUSTIN, Texas, March 08, 2018 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that its management will provide a corporate overview at the Cowen and Company 38th Annual Health Care Conference, taking place March 12-14 at the Boston Marriott Copley Place in Boston, MA.
| Presentation Details | |
| Date: | Tuesday, March 13 |
| Time: | 11:20am Eastern Time |
| Location: | The Boston Marriott Copley Place |
| Webcast: | http://wsw.com/webcast/cowen46/mtem/ |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact:
Andrew McDonald, Ph.D.
[email protected]
646-597-6987
Adam Cutler
Chief Financial Officer
[email protected]
862-204-4006
